Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q1 FY27 Earnings Presentation
26 slides from Jagsonpal Pharmaceuticals's earnings presentation, Jul 29, 2026
Slide 1: Exchange filing cover letter
July 29, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 5
Slide 2: Jagsonpal Pharmaceuticals Ltd announces Q1 FY27 Results
Jagsonpal Pharmaceuticals Ltd announces Q1 FY27 Results Strong Start to FY27 Revenue up 9%, PAT up 22% and cash reserves at ₹1,700 Mn; Aequitas – Strong platform for foray into hospital business Gurugram, July 29, 2026: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced
Slide 3: CEO commentary and about Jagsonpal
Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said, “Q1FY27 reflects sustained traction in our business, with revenue growing 9% YoY, driven by higher MR productivity and continued strength across our key brands. We signific
Slide 4: Jagsonpal Pharmaceuticals Limited Q1FY27
Jagsonpal Pharmaceuticals Limited Q1FY27 Investor Presentation 29th July 2026 1
Slide 5: Safe Harbor
Safe Harbor This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 6: Management Commentary
Management Commentary "Q1FY27 reflects sustained traction in our business, with revenue growing 9% YoY, driven by higher MR productivity and growth across key brands. We significantly outperformed the industry, with Pharmarack reporting 18.9% growth for Jagsonpal versus 11.6% for the IPM, leading to
Slide 7: Q1 FY27 Highlights
Q1 FY27 Highlights 4 4
Slide 8: Strong Financial Delivery In Q1 FY27
Strong Financial Delivery In Q1 FY27 Q1FY27 Rev up 9% | Op. EBITDA up 21% | PAT up 22% | Cash balance at ₹ 1,700 Mn Consistent revenue trajectory Q1 revenue stood at ₹ 822 Mn and delivered a 9% YoY growth. EBITDA Expands ahead of revenue Op. EBITDA of ₹ 191 Mn, an uptick of 21.4% YoY; Margin at 23.2
Slide 9: Financial Highlights: Q1 FY27
Financial Highlights: Q1 FY27 (All values in ₹ Mn) Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT & Margin (%) Q1FY26 Q1FY27 +66 Mn +49 Mn (+8.8%) (+10.1%) +34 Mn +24 Mn 822 (+21.4%) (+22.2%) 756 536 191 487 157 132 108 64.4% 65.2% 20.8% 23.2% 14.3% 16.0% 6 * EBITDA and E
Slide 10: Income Statement
Income Statement (All values in ₹ Mn) Particulars Q1 FY27 Q4 FY26 % Change Q1 FY26 % Change Revenue from Operations 822 642 28.1% 756 8.8% Total Expenses (632) (537) 17.7% (599) 5.4% EBITDA* 191 106 80.7% 157 21.4% EBITDA Margin* 23.2% 16.4% 41.1% 20.8% 11.6% Other Income 28 32 -10.6% 28 0.3% ESOP C
Slide 11: Key Balance Sheet Items
Key Balance Sheet Items (All values in ₹ Mn) Particulars 30-Jun-26 31-Mar-26 30-Jun-25 Shareholders Funds* 2,548* 2,762 2,535 Tangible Assets 6 6 6 Intangibles 763 780 837 Right of Use Assets 64 68 80 Financial Assets (Cash & Equivalents) 1,700 1,907 1,609 Other Non-Current Assets (Net) 28 26 48 Lea
Slide 12: Power Brand Building: Niche Dominators Driving Growth
Power Brand Building : Niche Dominators Driving Growth Top 10 brands constitutes ~ 58% of revenue, with 9 of them ranked in top #5 Brand MAT Molecule MAT Rank Brand Jun'26 Jun'25 Gr% Jun'26 Jun'25 Gr% 1 Indocap 41 39 4% 54 52 4% 2 Maintane Inj. 34 24 43% 166 135 23% 2 Metadec 26 24 5% 144 153 -5% 1
Slide 13: Consistent delivery of Operational Excellence
Consistent delivery of Operational Excellence FY22-26: PAT 2.4x; Cash balance 2.5x; FCF 8x Revenue (Rs Mn) Gross Profit (Rs Mn)* Op. EBITDA (Rs Mn)* CAGR CAGR CAGR 7.2% 9.1% 24.9% 2,872 1,829 609 2,176 1,286 250 FY22 FY26 FY22 FY26 FY22 FY26 Operational PAT (Rs Mn) Cash position (Rs Mn) FCF* (Rs Mn)
Slide 14: Excellence across Key Performance Parameters
Excellence across Key Performance Parameters Working capital reduced 69%; Dividend payout increased 2.5x; PAT margins expanded 700 bps while FCF conversion reached 92% CAPITAL EFFICIENCY SHAREHOLDER RETURNS CASH GENERATION Capital Optimized for Growth Rewarding shareholders, enhancing payouts Strong
Slide 15: Aequitas Healthcare Acquisition
Aequitas Healthcare Acquisition Accelerating Jagsonpal into a Leading Specialty Pharma Company A strategically transformative acquisition that expands our specialty portfolio, enhances hospital access, improves scale and accelerates our long-term growth trajectory. KEY INVESTMENT HIGHLIGHTS SPECIALT
Slide 16: About Aequitas
About Aequitas ₹PAN India Hospital Platform with 1,000+ Relationships COMPANY SNAPSHOT BUSINESS FOOTPRINT 1,000+ HOSPITALS Top Customers 7 YEARS OLD Strong presence across Established specialty-focused pharmaceutical company pan-India hospital chains Medanta Headquartered in Mumbai 4,000+ DOCTORS Ma
Slide 17: The Value Creation Roadmap
The Value Creation Roadmap Creating a ₹10 Cr EBITDA Opportunity Through Scale, Synergies & Integration EXPANDED BUSINESS REACH (FY27E) SYNERGY ROADMAP → VALUE CREATION JPL Aequitas Combined REVENUE SYNERGIES COST SYNERGIES Cross-sell JPL portfolio across 1,000+ Elimination of duplicate overheads Hos
Slide 18: Integration Progress
Integration Progress Key Initiatives & Strategic Benefits KEY INITIATIVES Ventrixa Cross-sell Supply Chain Finance Launched Opportunity • Aztreonam + Avibactam combination launched. • Cross-sell of JPL • Areas of integration • Governance structure brands to be initiated identified & initiated aligne
Slide 19: About the Company
About the Company 16 16
Slide 20: Jagsonpal - Legacy of 'Quality and Trust' since 1964
Jagsonpal - Legacy of ‘Quality and Trust’ since 1964 Deep Market Penetration Quality culture imbibed across Enduring Doctor Confidence Operations 100% India Centric Presence across 4000+ towns Trusted by >50,000 doctors Business and cities through 1200+ CMOs fully complaint with WHO- nationwide – a
Slide 21: Strong Presence in Key Therapies
Strong Presence in Key Therapies Gynecology Orthopedics o 7th as per CMARC RPM in CVM o 2nd as per CMARC RPM in CVM o Reaching ~90% of the Gynecologists o Reaching ~80% of the Orthopedists through nationwide, engagement with 35,000 out of consistent engagement with 10,000 out of 39,000 gynaecs. 13,0
Slide 22: Building A High-impact Asset Light Model
Building A High-impact Asset Light Model Capital Intensive Activities - Out-Sourced Ideation Research & Development Contract Manufacturing PAN-India Distribution In-house Ideation For Innovative Drug Concepts. 1-2 Partner with leading CDMO Partner with leading 1000+ Medical Reps for brand New Produc
Slide 23: Strategic Pillars
Strategic Pillars Innovation - Niche Large, well Molecules, trained Dominant Market Work Force Share of 1000+ Medical Reps Lean Operations: Inorganic Growth Asset Light Powered by Model Strategic Acquisition 20
Slide 24: MySakhi Initiative
MySakhi Initiative Where Business Meets Social Impact 18 pink toilets built in Haryana, Punjab, Uttarakhand & Delhi NCR Regions Driving Menopause Transforming Hygiene Access Awareness Collaborating with Built modern sanitation Deliver impactful virtual sessions NGOs for hygiene complexes across Punj
Slide 25: Key CSR Highlights - FY26
Key CSR Highlights - FY26 Sanitation Awareness Relief Empowering education with dignity and hygiene Creating safe spaces and healthier lives Standing with communities in times of crisis • 9 toilet blocks constructed in • MySakhi Initiative: Collaborating • Provided financial aid to flood- FY25-26 ac
Slide 26: Thank You
Thank You Feel free to reach out to us if you have any questions JAGSONPAL PHARMACEUTICALS LTD. Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi – 110020 cs@jagsonpal.com www.jagsonpal.com +91 124 4406710 INVESTOR RELATIONS Soumya Chhajed Email: soumya@goindiaadvisors.com
Jagsonpal Pharmaceuticals — Q1 FY27 Earnings Presentation on 6ix